· Published by Health Canada · Official notice
This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
August 21, 2012
Dear Health Care Professional:
Subject: Gilenya* (fingolimod) - Stronger recommendations regarding first-dose cardiovascular monitoring and use in patients with pre-existing cardiovascular conditions
Novartis Pharmaceuticals Canada Inc. ("Novartis"), in collaboration with Health Canada, would like to inform you about important new safety and use recommendations which have been added to the Product Monograph for Gilenya* (fingolimod), a drug indicated for the treatment of relapsing-remitting multiple sclerosis.
Isolated delayed-onset cardiovascular events, including transient asystole and unexplained death, have occurred within 24 hours of the first dose of Gilenya*. Health Canada has completed its review, which included a number of international reports of deaths, several of which were considered possibly associated with Gilenya*. No deaths have been reported in Canada. Fifty-four (54) Canadian case reports of serious cardiovascular adverse events, possibly associated with Gilenya* have been reported between March 09, 2011 and January 31, 2012. The majority of these cases have occurred within 6 hours of the first dose and consisted of bradycardia, hypertension, hypotension and dizziness/malaise/palpitations. The Canadian patient exposure to Gilenya* from April 1, 2011 to December 31, 2011 was estimated at 155.3 patient-yearsFootnote 1 from at least 621 patientsFootnote 2.
New recommendations to reduce the risk of cardiovascular events in patients taking Gilenya* have been included in the Warnings and Precautions section of the Product Monograph.
Gilenya* is indicated as monotherapy for the treatment of adult patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of physical disability. Gilenya* is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, one or more therapies for multiple sclerosis.
The Product Monograph for Gilenya* has been updated to include additional new recommendations. For complete prescribing information and conditions of use, please review the revised Product Monograph before prescribing Gilenya*.
Additional monitoring until the finding has resolved is also required:
If Gilenya* therapy is discontinued for more than 2 weeks, after the first month of treatment, the effects on heart rate and AV conduction may recur on reintroduction of Gilenya* treatment and the same precautions as for initial dosing should apply (i.e., monitor for at least 6 hours after the first dose). Within the first 2 weeks of treatment, first dose procedures are recommended after interruption of one day or more, during week 3 and 4 of treatment first dose procedures are recommended after treatment interruption of more than 7 days.
This communication follows up a 2012-02-27 Health Canada information update. For the complete changes to prescribing information, see the full Product Monograph, which may be accessed on the Health Canada website.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious cardiovascular event or other serious or unexpected adverse reactions in patients receiving Gilenya* should be reported to Novartis or Health Canada.
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval, (QC) H9S 1A9
Telephone: 1-800-363-8883 (Medical Information)
To correct your mailing address or fax number, contact Novartis Pharmaceuticals Canada Inc.
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions or require additional information regarding the use of Gilenya*, please contact Novartis Pharmaceuticals Canada Inc., Medical Information Department at 1-800-363-8883.
Sincerely,
original signed by
Jean Godin, M.D.
Chief Scientific Officer and Vice-President Clinical and Regulatory Affairs
*Gilenya is a registered trademark.
Calculation of patient-years derived from data supplied by IMS Health Canada Inc. - IMS Santé Canada Inc. (IMS)
Patient number derived from data supplied by the Gilenya* Go Program™